09/678,851

```
     (FILE 'HOME' ENTERED AT 11:03:46 ON 23 JUN 2003)

     FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 11:03:58 ON 23
     JUN 2003
L1            24 S GRYPHON
L2            21 DUP REM L1 (3 DUPLICATES REMOVED)
L3           600 S (OFFORD, R? OR OFFORD R?)/AU,IN
L4         11124 S (THOMPSON, D? OR THOMPOSON D?)/AU,IN
L5           358 S (WILKEN, J? OR WILKEN J?)/AU,IN
L6         12021 S L3 OR L4 OR L5
L7           157 S L6 AND (RANTES OR CHEMOKIN?)
L8             0 S L7 AND ACETYLAT?
L9             0 S L7 AND ACYLAT?
L10           75 S L7 AND (DERIVATIV? OR ANALOG? OR VARIANT? OR N-TERMIN?)
L11            3 S L10 AND HOMOLOG?
L12            3 DUP REM L11 (0 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 11:07:28 ON 23 JUN 2003

     FILE 'MEDLINE, WPIDS' ENTERED AT 11:09:24 ON 23 JUN 2003

     FILE 'STNGUIDE' ENTERED AT 11:09:26 ON 23 JUN 2003
L13            0 S (CHEMOKIN? OR RANTES)(10A)(HEXANOYL OR ALKANOYL? OR NONANOYL?
L14            0 S (CHEMOKIN? OR RANTES) AND(HEXANOYL OR ALKANOYL? OR NONANOYL?

     FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 11:11:15 ON 23
     JUN 2003
L15           56 S (CHEMOKIN? OR RANTES) AND(HEXANOYL OR ALKANOYL? OR NONANOYL?
L16           42 DUP REM L15 (14 DUPLICATES REMOVED)
L17           17 S (CHEMOKIN? OR RANTES)(20A)(HEXANOYL OR ALKANOYL? OR NONANOYL?
L18           11 DUP REM L17 (6 DUPLICATES REMOVED)
L19          185 S (CHEMOKIN? OR RANTES)(20A)(ACETYL? OR N-ACETYL?)
L20            3 S L19 AND ALKYLAT?
L21            0 S L19 AND (NONANOYL? OR DECANOYL? OR OCTANOYL?)
L22           24 S (CHEMOKINE? OR RANTES?) AND (NONANOYL? OR DECANOYL? OR OCTANO
L23           13 DUP REM L22 (11 DUPLICATES REMOVED)

=>
```

12 ANSWER 3 OF 3 MEDLINE

AN 1999214286 MEDLINE

DN 99214286 PubMed ID: 10196243

TI Highly potent **RANTES analogues** either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using **variants**.

AU Mosier D E; Picchio G R; Gulizia R J; Sabbe R; Poignard P; Picard L; **Offord R E; Thompson D A; Wilken J**

CS Department of Immunology-IMM7, The Scripps Research Institute, La Jolla, California 92037, USA.. dmosier@scripps.edu

NC AI29182 (NIAID)
MO1 RR00833 (NCRR)

SO JOURNAL OF VIROLOGY, (1999 May) 73 (5) 3544-50.
Journal code: 0113724. ISSN: 0022-538X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; AIDS

EM 199905

ED Entered STN: 19990601
Last Updated on STN: 19990601
Entered Medline: 19990519

AB The natural ligands for the CCR5 **chemokine** receptor, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and **RANTES** (regulated on T-cell activation, normal T-cell expressed and secreted), are known to inhibit human immunodeficiency virus (HIV) entry, and **N-terminally** modified **RANTES analogues** are more potent than native **RANTES** in blocking infection. However, potent CCR5 blocking agents may select for HIV-1 **variants** that use alternative coreceptors at less than fully inhibitory concentrations. In this study, two **N-terminal** chemical modifications of **RANTES** produced by total synthesis, aminooxypentane (AOP)-**RANTES**[2-68] and N-nonanoyl (NNY)-**RANTES**[2-68], were tested for their ability to prevent HIV-1 infection and to select for coreceptor switch **variants** in the human peripheral blood lymphocyte-SCID mouse model. Mice were infected with a CCR5-using HIV-1 isolate that requires only one or two amino acid substitutions to use CXCR4 as a coreceptor. Even though it achieved lower circulating concentrations than AOP-**RANTES** (75 to 96 pM as opposed to 460 pM under our experimental conditions), NNY-**RANTES** was more effective in preventing HIV-1 infection. However, in a subset of treated mice, these levels of NNY-**RANTES** rapidly selected viruses with mutations in the V3 loop of envelope that altered coreceptor usage. These results reinforce the case for using agents that block all significant HIV-1 coreceptors for effective therapy.

=>

WEST Search History

DATE: Monday, June 23, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR		
L14	L13 and (chemokin$ or RANTES)	8	L14
L13	L12 and l11	18	L13
L12	(offord or thompson or wilken)	102679	L12
L11	gryphon	111	L11
L10	L9 and acetylat$	6	L10
L9	(chemokin$ or RANTES)near10 (N-termin$)near20(analog$ or derivativ$ or variant$)	25	L9
L8	(chemokin$ or RANTES)near10 (N-termin!!!)near20(analog!!! or derivativ!!! or variant$)	0	L8
L7	chemokin$ near10 (N-termin$)near30 (acylate!! or acylation!! or alkylat!!!)	0	L7
L6	chemokin$ near30 (acylat$ or alkyl$)	43	L6
L5	chemokin$ near30 (N-alkyl)	0	L5
L4	chemokin$ near30 (nonanoyl or pentanoyl or hexanoyl or decanoyl)	0	L4
L3	RANTES near30 (nonanoyl or pentanoyl or hexanoyl or decanoyl)	2	L3
L2	L1 and (nonanoyl or pentanoyl or hexanoyl or decanoyl)	31	L2
L1	(inflamm$) and RANTES	1342	L1

END OF SEARCH HISTORY